厄洛替尼联合长春瑞滨治疗老年晚期食管癌的疗效分析  

Efficacy of erlotinib combined with vinorelbine in the treatment of senile advanced esophageal cancer

作　　者：金灵莉[1] 杜致远 吕飞[1] 尚瑞[1] 卢光新[1] JIN Ling-li;LV Fei;SHANG Rui;LU Guang-xin(Department of Gastroenterology, Shiyan People＇s Hospital, Shiyan 442000, Chin;DU Zhi-yuan. Information and Network Center, Hubei Medical University, Shiyan 442000, China)

机构地区：[1]十堰市人民医院消化内科,湖北省十堰市442000 [2]湖北医药学院信息网络中心,湖北省十堰市442000

出　　处：《实用老年医学》2018年第6期543-547,共5页Practical Geriatrics

摘　　要：目的探讨厄洛替尼联合长春瑞滨治疗老年晚期食管癌病人的疗效。方法选取2012年12月至2015年2月我院因晚期食管癌需治疗的老年病人96例,按入院时间分为观察组和对照组,每组48例。2组均予以紫杉醇、顺铂联合5-氟尿嘧啶化疗,观察组在此基础上予以厄洛替尼联合长春瑞滨,对照组则仅予以长春瑞滨。治疗6周后,比较2组临床效果、肿瘤标志物、免疫功能、Karnofsky功能状态评分(KPS评分)、血管内皮生长因子(VEGF)、C反应蛋白(CRP)、巨噬细胞炎性蛋白-3α(MIP-3α)、基质金属蛋白酶-2(MMP-2)、MMP-9、不良反应,并随访1年和2年生存率。结果观察组治疗后完全缓解率、部分缓解率、总有效率、KPS评分、CD3+、CD4+、CD4+/CD8+、1年生存率和2年生存率均高于对照组,CD8+、CRP、MIP-3α、VEGF、MMP-2、MMP-9、肿瘤标志物水平及不良反应发生率均低于对照组,差异均有统计学意义(均P<0.05)。结论厄洛替尼联合长春瑞滨治疗老年晚期食管癌临床效果较好,可提高免疫力,改善健康状况,毒性小,值得临床广泛应用推广。Objective To investigate the effect of erlotinib combined with vinorelbine in elderly patients with advanced esophageal cancer. Methods Ninety-six elderly patients with advanced esophageal cancer in our hospital from December 2012 to February 2015 were divided into observation group and control group,with 48 cases in each group. Both groups were given paclitaxel,cisplatin combined with 5-fluorouracil. On the basis of this,the observation group was treated with erlotinib combined with vinorelbine,and the control group was only given vinorelbine. The clinical effects,tumor markers,immune function, Karnofsky tumor patients＇ physical condition score（ KPS）, vascular endothelial growth factor（ VEGF）,C-reactive protein（ CRP）,macrophage inflammatory protein-3α（ MIP-3α）,matrix metalloproteinase-2（ MMP-2）,matrix metalloproteinase-9（ MMP-9）,adverse reaction,1-year survival rate and 2-year survival rate were compared between two groups. Results After treatment,the complete remission rate,partial remission rate,total effective rate,KPS,the levels of CD3＋,CD4＋,CD4＋/CD8＋,one-year survival rate and two-year survival rate in observation group were higher than those in control group,and the levels of CD8＋,CRP,MIP-3α,VEGF,MMP-2,MMP-9,tumor markers and the incidence of adverse reactions in observation group were lower than those in control group（ P〈0. 05）. Conclusions The combination of erlotinib and vinorelbine in the treatment of elderly patients with advanced esophageal cancer has a good clinical effect,which can improve immunity and health condition with little toxicity.

关 键 词：厄洛替尼 长春瑞滨 晚期食管癌 老年人 肿瘤标记物 免疫学指标 

分 类 号：R735.1[医药卫生—肿瘤]